89% and 84% of patients were maintained on ≥12- and ≥16-week dosing intervals, respectively, throughout the two-year period, while sustaining their...
Acquisition to Enhance Xtant’s Growing Spinal Fusion Devices Portfolio BELGRADE, Mont., July 28, 2023 (GLOBE NEWSWIRE) -- Xtant Medical Holdings,...
DEERFIELD, Ill., July 28, 2023 (GLOBE NEWSWIRE) -- Surgalign Holdings, Inc., (OTC: SRGAQ) (“Surgalign” or the “Company”), a global medical...
Presentations represent the first time clinical data regarding ARX517 will be presented at a medical meetingSAN DIEGO, July 28, 2023...
UTRECHT, The Netherlands and CAMBRIDGE, Mass., July 28, 2023 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we,...
TORONTO, July 28, 2023 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a...
CHATHAM, N.J., July 27, 2023 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a biopharmaceutical...
Exercise of Procurement Options of Approximately $113 Million for Oral TPOXX and Approximately $25 Million for IV TPOXX under Current...
Appointment adds Dr. Powchik’s experience in the development of marketed immunotherapeutics to Vaxxinity’s leadership team CAPE CANAVERAL, Fla., July 27,...
Raises 2023 GuidanceNASHVILLE, Tenn.--(BUSINESS WIRE)--HCA Healthcare, Inc. (NYSE:HCA), today announced financial and operating results for the second quarter ended June...
SAN DIEGO, July 27, 2023 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (OTC: SRNEQ, "Sorrento"), a biopharmaceutical company dedicated to the...
NEW YORK and LONDON, July 27, 2023 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing...
Preliminary data suggest a chlamydia, gonorrhea and trichomonas (CT/NG/TV) multiplex test is feasible on a molecular point-of-care (POC) test system...
NEW YORK, July 27, 2023 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today announced...
-- Number of subjects increased from 12 to 60 ---- Portable Neuromodulation Stimulator (PoNS®) will be used to evaluate cranial-nerve...
55% objective response rate; 23% complete response rate in locally advanced cSCC 50% objective response rate; 13% complete response rate...
Anaphylm 12mg Exceeds Lower Bracket at All Expected Pivotal Targets Anaphylm 12mg Exceeds Lower Bracket at All Expected Pivotal TargetsReports...
Interim safety data from the Phase 2 DAVIO 2 trial continues to demonstrate EYP-1901 is well tolerated with no reported...
WATERTOWN, Mass., July 27, 2023 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein...
PHOENIX, AZ / ACCESSWIRE / July 26, 2023 / The Stock Day Podcast welcomed CLS Holdings USA, Inc. (CLSH) ("the...